Financial Performance - The company expects a net profit for 2025 to be positive but to decline by over 50% compared to the previous year[2] - The net profit attributable to shareholders is projected to be 27.20 million yuan, a decrease of 55% from the previous year's profit of 60.45 million yuan[3] - The net profit after deducting non-recurring gains and losses is estimated at 20.12 million yuan, also down 55% from 44.70 million yuan in the same period last year[3] Expenses and Costs - Increased sales expenses due to intensified efforts in the formulation market development have impacted overall profitability[5] - Management expenses have risen due to payments related to restructuring intermediary fees[5] - The company has increased R&D investment to support its "innovation-driven development" strategy, leading to higher R&D expenses[5] - There has been a reduction in government subsidies related to daily operations, resulting in decreased other income[5] Asset Management - The company has conducted a comprehensive review of receivables and plans to recognize asset impairment losses, which will increase overall asset impairment losses[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2025 annual report[7] - Investors are advised to be aware of investment risks associated with the preliminary earnings forecast[7]
科源制药(301281) - 2025 Q4 - 年度业绩预告